Are tsDMARDs Approved for Crohn's Disease?
No, targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) are not approved for Crohn's disease. tsDMARDs, specifically JAK inhibitors like tofacitinib, baricitinib, and upadacitinib, are approved for rheumatoid arthritis and other rheumatologic conditions, but not for inflammatory bowel disease including Crohn's disease 1, 2.
Current Approved Therapies for Crohn's Disease
The 2021 AGA guidelines clearly outline approved treatments for moderate-to-severe Crohn's disease 2:
- Anti-TNF agents (infliximab, adalimumab, certolizumab pegol) - strongly recommended
- Vedolizumab (integrin inhibitor) - conditionally recommended
- Ustekinumab (IL-12/23 inhibitor) - strongly recommended
Notably absent from this list are any tsDMARDs/JAK inhibitors, as they lack FDA approval for Crohn's disease.
Why the Confusion May Exist
The terminology can be confusing because:
- tsDMARDs are extensively used in rheumatology for conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis 1, 3, 4
- Some JAK inhibitors ARE approved for ulcerative colitis (tofacitinib, upadacitinib) 5, 6, but this approval does NOT extend to Crohn's disease
- Research has explored tofacitinib as a potential therapy for Crohn's disease 7, but it has not achieved regulatory approval
Critical Distinction for Inflammatory Bowel Disease
When managing patients with spondyloarthritis who also have inflammatory bowel disease, guidelines specifically address this 5:
- Monoclonal antibody TNF inhibitors are strongly recommended for patients with axial spondyloarthritis and IBD
- JAK inhibitors are only conditionally recommended for ulcerative colitis when TNF inhibitors are contraindicated or unavailable
- For Crohn's disease specifically, only infliximab, adalimumab, and certolizumab are approved 5
Common Pitfall to Avoid
Do not extrapolate approvals across disease states. Just because upadacitinib recently gained approval for Crohn's disease in some countries 5 does not mean all JAK inhibitors are approved, and approval status varies significantly by region and regulatory body.
Bottom line: If treating Crohn's disease, stick with the approved biologics (anti-TNF agents, vedolizumab, ustekinumab). tsDMARDs/JAK inhibitors remain investigational for Crohn's disease and should not be used outside of clinical trials.